Archford Capital Strategies LLC Sells 21,216 Shares of Global X Genomics & Biotechnology ETF $GNOM

Archford Capital Strategies LLC decreased its position in shares of Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) by 77.7% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,083 shares of the company’s stock after selling 21,216 shares during the period. Archford Capital Strategies LLC owned approximately 0.50% of Global X Genomics & Biotechnology ETF worth $236,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Flow Traders U.S. LLC raised its stake in shares of Global X Genomics & Biotechnology ETF by 52.4% in the second quarter. Flow Traders U.S. LLC now owns 238,725 shares of the company’s stock valued at $2,012,000 after acquiring an additional 82,063 shares during the period. Jane Street Group LLC grew its holdings in Global X Genomics & Biotechnology ETF by 7.7% during the 1st quarter. Jane Street Group LLC now owns 143,713 shares of the company’s stock valued at $1,143,000 after purchasing an additional 10,308 shares during the last quarter. Oppenheimer Asset Management Inc. raised its position in Global X Genomics & Biotechnology ETF by 8.1% in the 2nd quarter. Oppenheimer Asset Management Inc. now owns 89,631 shares of the company’s stock worth $756,000 after purchasing an additional 6,708 shares during the period. Insight Advisors LLC PA lifted its stake in Global X Genomics & Biotechnology ETF by 47.9% in the second quarter. Insight Advisors LLC PA now owns 59,675 shares of the company’s stock worth $503,000 after purchasing an additional 19,319 shares during the last quarter. Finally, Sei Investments Co. boosted its position in shares of Global X Genomics & Biotechnology ETF by 110.4% during the second quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock valued at $194,000 after buying an additional 12,105 shares during the period. Hedge funds and other institutional investors own 56.95% of the company’s stock.

Global X Genomics & Biotechnology ETF Trading Down 1.1%

NASDAQ:GNOM opened at $46.67 on Tuesday. The company has a market cap of $56.94 million, a price-to-earnings ratio of -19.94 and a beta of 1.22. Global X Genomics & Biotechnology ETF has a twelve month low of $27.20 and a twelve month high of $48.09. The stock has a fifty day simple moving average of $45.15 and a 200-day simple moving average of $39.64.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.